Status:
WITHDRAWN
Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Integrated Therapeutics Group
Conditions:
Hepatitis C
Liver Cirrhosis
Eligibility:
All Genders
18-69 years
Phase:
PHASE3
Brief Summary
This is a Phase 3b, randomized, open-label, parallel-group, multi-center, multi-national study of low-dose maintenance Peg interferon alpha-2b (Peg-Intron®) in subjects with human immunodeficiency vir...
Eligibility Criteria
Inclusion
- Age at least 18 years but \< 70 years, of either sex or any race.
- Detectable plasma hepatitis C virus (HCV) RNA (all genotypes of HCV are permitted).
- Cirrhosis of the liver within the last five years.
- Compensated liver disease (Child-Pugh \<8 with hepatic encephalopathy \<= 1.
- No evidence of hepatocellular carcinoma (HCC) and a serum alpha fetoprotein (AFP) \<100 ng/mL within two months of randomization/study enrollment.
- Varices results via endoscopy within the last six months or at time of screening.
- Serologic evidence of human immunodeficiency virus-1.
- CD4 cell count \>=100 /µL.
- Platelet number of at least 50000 mm\*\*3.
- Neutrophil count of at least 750 mm\*\*3.
- Hemoglobin of \>9.0 mg%.
- Serum thyroid stimulating hormone levels within normal limits, regardless of treatment with L thyroxin.
- Hemoglobin A1c (HbA1c)\<8.5%, to demonstrate controlled diabetes, if applicable.
- Written clearance from an ophthalmologist must be presented for subjects with a history of hypertension or diabetes prior to treatment start.
- Creatinine clearance \>50 mL/min, as assessed by the indirect calculation method.
- Demonstrate stable status of HIV-1 infection.
- On stable antiretroviral therapy (HAART) for at least 6 weeks prior to baseline, with the expectation of their HAART regimen (drugs and dosage) remaining unaltered for the first 8 weeks of the study OR
- Willing to delay initiation of HAART therapy for at least 6 weeks (for subjects who have not been on HAART for at least 8 weeks prior to randomization). "Structured treatment interruptions" will be permitted during the study.
- Counseled in the appropriate use of birth control while in this study, as confirmed by the principal investigator or a sub-investigator.
- Free of any clinically significant disease (other than HCV and HIV) that would interfere with study evaluations.
Exclusion
- Female who is pregnant, intends to become pregnant during the study or within two months after study completion, or is nursing. Male subject whose partner wants to become pregnant.
- Using silymarin.
- Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, or HBeAg.
- Any cause of liver disease other than chronic hepatitis C.
- Suspected or having hypersensitivity to interferon.
- History of liver decompensation status or other evidence of bleeding from esophageal varices, signs of current bleeding, significant ascites, hepatic encephalopathy, jaundice or other conditions consistent with decompensated liver disease.
- Present with a lesion suspicious for hepatic malignancy on the screening imaging.
- Any active malignant disease, suspicion, or history of malignant disease within 5 years prior to study enrollment (except for adequately treated basal cell carcinoma).
- Known coagulation or hemoglobin diseases.
- Organ transplant, except corneal or hair transplant.
- Any known preexisting medical condition that, in the investigator's opinion, could interfere with the subject's participation in and completion of the study, such as major depressive disorder.
- Active HIV-related opportunistic infection and/or malignancy requiring systemic therapy.
- Evidence of known severe retinopathy.
- Subject has not observed the designated washout periods for any of the prohibited medications.
- Participating in any other hepatitis C clinical study.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00381017
Start Date
September 1 2006
Last Update
August 13 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.